智通财经APP讯，今海医疗科技(02225)发布公告，公司的全资附属公司上海今海协寰医疗科技有限公司(今海协寰)近期与国药控股菱商医院管理服务(上海)有限公司(国药菱商)订立销售总协议，据此，今海协寰授权国药菱商为集团若干高端医疗器械于中国的独家分销商，期限至2025年10月。
国药菱商为由国药控股股份有限公司与日本三菱商事株式会社共同成立的合营公司。作为医用耗材综合运营服务提供商，国药菱商致力于打造以大数据为基础、信息系统互联互通的数字化供应链服务平台，为客户提供全供应链解决方案。凭借国药菱商广泛的分销网络及强大的市场影响力，集团的主要产品可望于更广阔的市场上亮相，实现快速增长。特别是集团的4K3D 萤光内窥镜、椎间孔内窥镜及配套仪器包，已显示出强劲市场竞争力及增长潜力。公司一直主动发展集团的业务，旨在扩阔其收入来源，最终为股东带来最大回报。预期与国药菱商的合作将进一步巩固及扩大该等产品的市场占有率，为股东带来整体正面回报。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.